A multicenter phase II study of Q3 week or weekly paclitaxel in combination with bevacizumab for the treatment of metastatic or unresectable angiosarcoma

DOI Web Site Web Site 2 Citations
  • Nam Bui
    Stanford Cancer Institute, Stanford, CA, USA
  • Nikhil Kamat
    Department of Medicine, School of Medicine, Stanford University, Stanford, CA, USA
  • Vinod Ravi
    The University of Texas MD Anderson Cancer Center, Houston, TX, USA
  • Sant Chawla
    Sarcoma Oncology Center, Santa Monica, CA, USA
  • Marti Lohman
    Department of Medicine, School of Medicine, Stanford University, Stanford, CA, USA
  • Kristen N Ganjoo
    Stanford Cancer Institute, Stanford, CA, USA

Search this article

Description

<jats:p> Paclitaxel (P) and bevacizumab (B) are agents that provide clinical benefit in advanced angiosarcoma (AS). The objective of this study was to assess the efficacy and safety of P-B in two different scheduled regimens. Patients were to receive P 200mg/m2 IV with B 15mg/kg IV every 21 days (Regimen A) or P 90mg/m2 IV weekly D1, 8, 15 with B 15mg/kg IV D1 of a 28 day cycle (Regimen B) x6 cycles. Maintenance B followed at a dose of 15 mg/kg intravenously once every 21 days. The primary end point was 4 month non-progression rate (NPR). A total of 16 patients were enrolled. 4 month NPR was 62.5% with median overall survival 16 months and median progression free survival 5.06 months. 11 patients made it to cycle 3 and were evaluable for response with 1 CR (9%), 4 PR (36%), 2 SD (18%), and 6 PD (36%). There were ten grade 3 toxicities and four grade 4 toxicities. The breakdown between the two regimens revealed comparable efficacy and safety. Paclitaxel and Bevacizumab is an active regimen in angiosarcoma. Q3 week and weekly paclitaxel appear similar in efficacy and safety. </jats:p>

Journal

  • Rare Tumors

    Rare Tumors 10 2018-01-01

    SAGE Publications

Citations (2)*help

See more

Report a problem

Back to top